BeyondSpring (also known as Spring Pharmaceuticals) is a biopharmaceutical company focused on oncology therapies. Its lead asset, plinabulin, is a selective immunomodulating microtubule-binding agent that is being developed as a direct anti-cancer agent in combination with docetaxel, in combination with immuno-oncology regimens, as well as for the prevention of chemotherapy-induced neutropenia.